Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884302 | 0.91 | MAPK9 (0.44) | KDM4EMAPTMAPK1MERTKFLT3 | |
| SCHEMBL2883333 | 0.78 | MKNK1 (0.45) | KCNH3KDM4ENPC1HTTRAB9A | |
| SCHEMBL27514125 | 0.78 | ULK1 (0.41) | NPC1RAB9AMKNK1MKNK2ADORA1 | |
| SCHEMBL2883441 | 0.77 | OGA (0.53) | KCNH3KDM4EMAPTHTTRAB9A | |
| SCHEMBL5102956 | 0.77 | CDK4 (0.53) | KDM4ENPC1RAB9AMERTKTYRO3 | |
| SCHEMBL28742511 | 0.75 | OGA (0.40) | MKNK1MKNK2HRH4 | |
| SCHEMBL27537476 | 0.75 | HTR7 (0.49) | MAPTHTTHRH4 | |
| SCHEMBL27570733 | 0.75 | MRGPRX1 (0.40) | MKNK1MKNK2HRH4 | |
| SCHEMBL2883059 | 0.75 | OGA (0.38) | MKNK1MKNK2HRH4 | |
| SCHEMBL2878987 | 0.75 | MKNK1 (0.43) | KCNH3KDM4EMAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | claimed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | claimed |
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-11-08 | — | — | US | disclosed |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259892-A1 | METHOD OF INHIBITING THE EXPRESSION AND/OR THE ACTIVITY OF JNK | MAP3K20, MAPK3, MAPK10 | NUDT1 2306/4885KCNH3 1948/4885PIK3C3 704/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | NUDT1 4628/4885KCNH3 2595/4885PIK3C3 553/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | NUDT1 4335/4885KCNH3 3798/4885PIK3C3 1041/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | NUDT1 4123/4885KCNH3 4403/4885PIK3C3 825/4885 |
| US-20050119277-A1 | Benzazole derivatives for the treatment of scleroderma | SMAD3, SQOR, TNNI3 | NUDT1 3796/4885KCNH3 1142/4885PIK3C3 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.